| SEQ_NO | 2 | Date of announcement | 2024/06/12 | Time of announcement | 15:05:56 |
| Subject | Announcement of re-election of Directors at the 2024 Annual Shareholders' Meeting and the change of more than one-third of Directors | ||||
| Date of events | 2024/06/12 | To which item it meets | paragraph 6 | ||
| Statement | 1.Date of occurrence of the change:2024/06/12 2.Elected or changed position (Please enter institutional director, institutional supervisor, independent director, natural-person director or natural-person supervisor): institutional director, independent director 3.Title and name of the previous position holder: Director – Legal Representative of Medeon, Inc. Yue Teh Jang Director – Legal Representative of CENTER LABORATORIES INC. Jung Chin Lin Director – Legal Representative of CENTER LABORATORIES INC. Chih Hsiung Wu Director – Hong Jen Chang Director – Hsin Yuan Fang Independent Director – Chi Hang Yang Independent Director – Chia Ying Ma Independent Director – Jerome Shen Independent Director – Jien Wei Yeh 4.Resume of the previous position holder: Legal Representative of Medeon, Inc., Yue Teh Jang?GGM of Medeon Biodesign, Inc. Legal Representative of CENTER LABORATORIES INC., Jung Chin Lin?GDirector of BioGend Therapeutics Co.,Ltd. Legal Representative of CENTER LABORATORIES INC., Chih Hsiung Wu?GChairman of V-CHECK, INC. Hong Jen Chang?G Chairman and CEO, YFY Biotech Management Company Hsin Yuan Fang?GVice Superintendent of Department of Surgery, China Medical University Hospital Chi Hang Yang?GChairman, SVT Investment Co. , Ltd Chia Ying Ma?GProfessor, Department of Accounting , Soochow University Jerome Shen?GChairman of Taiwania Capital Biotechnology Corporation Jien Wei Yeh?GChair Professor, Department of Material Science Engineering, National Tsing Hua University 5.Title and name of the new position holder: Director – Legal Representative of Medeon, Inc., Yue Teh Jang Director – Legal Representative of CENTER LABORATORIES INC., Jung Chin Lin Director – Legal Representative of CENTER LABORATORIES INC., Chih Hsiung Wu Independent Director – Chi Hang Yang Independent Director – Chia Ying Ma Independent Director – Jien Wei Yeh Independent Director – Feng Shyang Yang 6.Resume of the new position holder: Legal Representative of Medeon, Inc., Yue Teh Jang?GGM of Medeon Biodesign, Inc. Legal Representative of CENTER LABORATORIES INC., Jung Chin Lin?GDirector of BioGend Therapeutics Co.,Ltd. Legal Representative of CENTER LABORATORIES INC., Chih Hsiung Wu?GChairman of V-CHECK, INC. Chi Hang Yang?GChairman, SVT Investment Co. , Ltd Chia Ying Ma?GProfessor, Department of Accounting , Soochow University Jien Wei Yeh?GChair Professor, Department of Material Science Engineering, National Tsing Hua University Feng Shyang Yang?GSupervisor, Adimmune Corporation 7.Circumstances of change (Please enter ‘resignation’, ‘dismissal’, ‘term expired’, ‘death’ or ‘new appointment’):term expired 8.Reason for the change: Term expired and re-elected Directors 9.Number of shares held by the new position holder when elected: Director – Legal Representative of Medeon, Inc. Yue Teh Jang; 10,450,911 shares Director – Legal Representative of CENTER LABORATORIES INC. Jung Chin Lin; 27,411,028 shares Director – Legal Representative of CENTER LABORATORIES INC. Chih Hsiung Wu; 27,411,028 shares Independent Director – Chi Hang Yang; 0 shares Independent Director – Chia Ying Ma; 0 shares Independent Director – Jien Wei Yeh; 0 shares Independent Director – Feng Shyang Yang; 0 shares 10.Original term (from __________ to __________):2021/07/16~2024/07/15 11.Effective date of the new appointment:2024/06/12 12.Turnover rate of directors of the same term:NA 13.Turnover rate of independent directors of the same term:NA 14.Turnover rate of supervisors of the same term:NA 15.Change in one-third or more of directors (Please enter ‘Yes’ or ‘No’):Yes 16.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 6 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):None |
||||